인사이트
Insights From Our Experts
Articles
The Expanding Oncology Market Prompts Reevaluation of Field Team Training Procedures and Skill Set to Impact Frontline Success
Since 2015, the oncology pipeline has grown by 75%. Simultaneous to the exponential pipeline growth, the market has become increasingly unpredictable with an abundance of challenges such as unprecedented speed to market, securing patient access and…
Pivot Pros: How EVERSANA Course Corrected When the Market Changed
Traditional commercialization models lack the insights, flexibility and agility to synthesize and react to real-time data. If you needed to quickly pivot your strategy to ensure the success of your therapy in market, would your commercialization…
Case Study: Benchmarking Pathway-Specific Engagement with Health Plans & Organized Providers to Identify Best Practices
Tapping into primary market research and subject matter expertise can help uncover opportunities to more effectively meet their needs and position your brand for inclusion within their pathways. As stakeholders seek to leverage oncology clinical pathways…
Payer Oncology Access Management in 2022
Payers balance the severity of disease with the need to control high-dollar utilization. As pharmacy spend continues to rise, payers are seeking ways to manage costs in the highest cost therapeutic areas, including oncology. While there is appetite…
Point of Attack: Developing a Targeted Oncology Account Engagement Strategy and Tactical Platform
Key account management (KAM) is a more innovative approach to pharmaceutical sales and account engagement. KAM promises to deliver long-term, mutually beneficial partnerships between biopharmaceutical manufacturers and healthcare systems and provider practices (aka target accounts). Pharmaceutical…
Reversing the Complexity of Oncology Commercialization: How to solve for launch challenges in a chaotic ecosystem
As physicians, patients and caregivers tirelessly fight complex diseases, a growing number of drug manufacturers are preparing to launch new oncology therapies. These high-science therapies are entering the market at rapid rates: Presently, there are 500…
A Partnership Q&A with EVERSANA and Shorla Pharma
As industry and patient needs progress beyond traditional commercialization models, new models are needed to deliver products to patients quicker, especially when launching in international markets. Still asking yourself how to execute on a global pharmaceutical product launch? EVERSANA has the answer to this question and others that you’ll have…
A YEAR OF ACTION: Why Data-Backed, Integrated Commercialization Strategies Are Must-haves in 2022
By applying transformative commercialization models, nurturing digital transformation and trailblazing in global expansion, we can get therapies to patients around the world who are still waiting for treatment options. For the past two years, the pharmaceutical…
Bio-Europe “Collaboration Close-Up”: Exploring the EVERSANA – Shorla Pharma Partnership
Launching in today’s unpredictable market is a journey with new challenges around every corner. While the oncology pipeline is rapidly growing, stringent competition and an evolving provider environment are putting intense pressure on manufacturers to build…